OXFORD, England and SAN JOSE, California, March 1, 2018 /PRNewswire/ -- Oxford BioTherapeutics ("OBT"), a clinical stage oncology company with a pipeline of immuno-oncology and antibody-drug conjugate based therapies, today announced the appointment of Abderrahim (Rahim) Fandi, M.D.,...
from PR Newswire: //http://ift.tt/2GTci7p
No comments:
Post a Comment